The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
BIM expression in EGFR-mutant non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib in Colombia.
Andres F. Cardona
No relevant relationships to disclose
Niki Karachaliou
No relevant relationships to disclose
Ana Drozdowskyj
No relevant relationships to disclose
Ana Gimenez Capitan
No relevant relationships to disclose
Miguel Angel Molina-Vila
No relevant relationships to disclose
Oscar Arrieta
No relevant relationships to disclose
Hernan Carranza
No relevant relationships to disclose
Carlos A. Vargas
No relevant relationships to disclose
Jorge M. Otero
No relevant relationships to disclose
Rafael Rosell
No relevant relationships to disclose